Amgen Inc. closed 19.88% short of its 52-week high of $346.85, which the company reached on July 25th.

Financial writer analysis of Arcutis Biotherapeutics, Inc. stock surge and potential growth, FDA approvals, and partnerships ...

Rep. Andy Ogles (R-Tenn.) proposed an amendment to the U.S. Constitution that would allow President Trump to serve a third ...

This December, Amgen received a second state incentive to expand its Holly Springs operations by adding another drug ...

We recently compiled a list of the 13 Highest Yielding Dividend Stocks in the Dow. In this article, we are going to take a ...

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a ...

Amgen executives and employees, local and state elected dignitaries, and an assortment of other local economic development ...

Amgen's dividend profile shines, but growth slows. See why AMGN stock faces regulatory risks and offers limited incentives ...

In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of ...

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

Today, Benzinga's options scanner spotted 11 options trades for Amgen. This isn't normal. The overall sentiment of these ...